|Bid||40.01 x 200|
|Ask||40.50 x 2900|
|Day's Range||40.17 - 40.49|
|52 Week Range||37.20 - 44.54|
|PE Ratio (TTM)||40.09|
|Dividend & Yield||1.99 (4.97%)|
|1y Target Est||N/A|
GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.
GlaxoSmithKline (GSK) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.